Future studies should explore whether interventions to reduce LCN2 can prevent age-related diseases, such as cardio-metabolic disease, osteoporosis, and sarcopenia, and whether LCN2 can be used as a biomarker for chronic disease. Here, LCN2 is linked to sarcopenia.